超声检查及血清CA125 EMAb测定诊断子宫腺肌病的临床评价

近年来 ,子宫腺肌病的发病率呈明显上升趋势 ,但有3 5 %患者无明显临床症状[1] 。因此 ,术前误诊、漏诊率高。ＭＲＩ诊断子宫腺肌病有很高的价值 ,但由于检查费用昂贵 ,不能广泛普及。为此 ,我们采用超声检查及测定血清ＣＡ12 5、ＥＭＡｂ水平 ,以探讨它们在子宫腺肌病诊断中的价值。1　资料与方法1 1研究对象　以我院妇产科 2 0 0 0年 1月至 2 0 0 1年 3月经手术治疗并经术后病理确诊的 68例子宫腺肌病和子宫肌瘤患者为研究对象。其中子宫腺肌病 3 8例为研究组 ,子宫肌瘤 3 0例为对照组。研究组平均年龄 ( 3 5 4 3± 5 84 )岁 ,对照组 ( …     

子宫肌瘤和子宫腺肌病患者血清CA125水平的研究

我们就子宫肌瘤和子宫腺肌病患者的血清ＣＡ12 5水平及其诊断价值进行分析研究 ,报道如下。1　资料与方法1 1　研究对象　选择 1998年 1月至 1999年 12月我院妇科因子宫肌瘤或 (和 )子宫腺肌病住院手术的患者 10 47例作为研究对象 ,均经术中及术后病理检查证实。根据手术所见和病理检查结果将病例分成 3组 :Ａ组 ( 787例 ) :单纯子宫肌瘤组 ;Ｂ组 ( 2 0 3例 ) :单纯子宫腺肌病组 ;Ｃ组 ( 5 7例 ) :子宫肌瘤合并子宫腺肌病组。1 2　方法　所有研究对象均在住院次日晨静脉采血 ,血液标本立即送实验室分离出血清 ,保存于 - 30℃的环境中 ,待测…     

联合测定血清EMAb和CA125对子宫内膜异位症的诊断价值

子宫内膜异位症 (ｅｎｄｏｍｅｔｒｉｏｓｉｓ ,ＥＭＴ)多见于生育期妇女 ,是引起下腹部疼痛的主要原因之一 ,其发病率各家报道不一 ,变化于 1%～ 5 0 %之间[1] 。腹腔镜是目前诊断ＥＭＴ的金标准 ,至今尚无一种简单有效的非损伤性的诊断方法 ,本文通过联合测定血清抗子宫内膜抗体 (ＥＭＡｂ)和ＣＡ12 5水平 ,以期为ＥＭＴ诊断提供一条新途径。1　资料与方法1 1　研究对象ＥＭＴ患者 34例 (ＥＭＴ组 ) ,年龄 2 1～ 4 6岁 ,平均为33 6岁 ,均为 1999年 11月至 2 0 0 1年 1月在我院妇科经手术病理诊断为ＥＭＴ住院患者。按修订的美国生育学会(…     

超声检查及血清CA125、EMAb测定诊断卵巢子宫内膜异位症的评价

超声检查及血清ＣＡ１２５、ＥＭＡｂ测定诊断卵巢子宫内膜异位症的评价张友忠许燕雪江森刘少平陈丽君（山东医科大学附属医院妇产科）卵巢是子宫内膜异位症（ｅｎｄｏｍｅｔｒｉｏｓｉｓ，ＥＭＴ）最易侵犯的部位〔１〕，近年来由于ＥＭＴ的发生率不断上升，卵巢ＥＭＴ...     

血清及腹腔液CA125测定对子宫腺肌病的诊断价值

目的探讨血清及腹腔液CA125测定对子宫腺肌病的诊断价值.方法采用免疫化学发光法测定28例子宫腺肌病和25例子宫肌瘤患者血清及腹腔液(110稀释)CA125水平.结果子宫腺肌病患者血清CA125水平高于子宫肌瘤患者,差异有显著性(P＜0.01).两组间腹腔液CA125水平差异无显著性(P=0.18).腹腔液CA125水平明显高于血清CA125水平(P＜0.01),但二者无明显相关性(P＞0.50).腺肌病患者血清CA125水平受子宫大小、大体病理类型、使用性激素等因素影响.结论如用于子宫腺肌病的辅助诊断,血清CA125测定较腹腔液CA125测定敏感.腹腔液中CA125的主要来源可能为腹膜上皮细胞.     

超声检查及血清CA125测定诊断子宫腺肌病的评价

目的探讨超声检查及血清癌抗原125(CA125)测定对子宫腺肌病的诊断价值.方法通过对120例疑为子宫腺肌病或子宫肌瘤患者,行术前腹部B超和血清CA125测定;术后切下组织送病理学检查确诊并与之对照.结果经术后病理学证实子宫腺肌病组术前血清CA125检测敏感度73.8%, 特异度73.5%; B超诊断该病的敏感度55.4%, 特异度64.8%; 以两种方法联合检测均阳性为诊断标准, 则敏感度52.5%, 特异度94.1%.结论测定血清CA125水平,对子宫腺肌病是较好的辅助诊断指标;B超检查对该病有一定诊断价值;两者联合检测能提高诊断的正确性,且方法简便、快捷、无创伤,是目前较为实用的诊断方法.     

动态监测CA125 EMAb对子宫动脉栓塞术治疗子宫腺肌病的疗效评价

目的采用血清CA125、子宫内膜抗体(EMAb)动态监测,评价子宫动脉栓塞术(UAE)治疗子宫腺肌病的疗效.方法 2002年3月至2004年3月对就诊于广州市妇婴医院、中山大学附属第三医院的86例确诊为子宫腺肌病患者,在UAE术前及术后连续动态监测血清CA125、EMAb之变化.结果血清CA125水平在UAE后第4周开始下降至(89±11.3)kU/L,和术前(128±44.3)kU/L比较,差异有显著性意义(P<0.05);术后CA125稳定下降,至18个月降至正常水平(<35kU/L);血清EMAb术前52例阳性,第2个月开始下降,和术前比较术后EMAb阳性率差异有显著性意义(P<0.05).结论血清CA125、EMAb动态监测UAE治疗子宫腺肌病的疗效,其方法简单且具有临床实用意义.     

联合测定子宫内膜异位症患者血清中EMAb及CA125的临床评价

目的：对联合测定子宫内膜异位症（内异症）患者血清中ＥＭＡｂ及ＣＡ１２５进行临床评价。方法：采取内异症１０９例术前（内异症组）和健康妇女３０例（对照组）空腹静脉血，用酶联免疫吸附法（ＥＬＩＳＡ）测定两组血清中ＥＭＡｂ水平；用放射免疫法（ＲＩＡ）测定血清中ＣＡ１２５水平。结果：内异症组ＥＭＡｂ阳性率为６３．３０％，对照组为１０％，两组差异有显著性（Ｐ＜０．０５）。内异症各期及子宫腺肌病间ＥＭＡｂ阳性率差异无显著性（Ｐ＞０．０５）。内异症组血清ＣＡ１２５水平平均为７０．７０±１６．６２Ｕ／ｍｌ，对照组为１５．３８±５．３２Ｕ／ｍｌ，两组差异有显著性。如以ＣＡ１２５≥３５Ｕ／ｍｌ为阳性界值，则内异症组阳性率为８０．２３％，对照组为６．６６％。单独测定ＥＭＡｂ诊断内异症的敏感性为６３．３０％，特异性为９０％；单独测定ＣＡ１２５诊断内异症的敏感性为８０．２３％、特异性为９３．３３％。如以两者均阳性为诊断标准，则敏感性为５７．８０％，特异性为１００％；如以其中之一阳性为诊断标准，则敏感性为９１．７４％，特异性为８３．３３％。结论：测定内异症患者血清中ＥＭＡｂ及ＣＡ１２５水平对内异症有较好的辅助诊断价值，联合测定ＥＭＡｂ及?     

子宫内膜异位症患者血清CA125测定

子宫内膜异位症患者血清ＣＡ＿（１２５）测定熊晓燕，舒明炎，高晓秋，刘惠兰，丛克家目前，子宫内膜异位症的诊断，主要依靠临床症状、体征及腹腔镜所见，而缺乏特异性手段。近年来研究发现，子宫内膜异位症患者血清ＣＡ＿（１２５）升高￣［１］。本研究对１１６例开腹...     

CA125对子宫内膜癌检测及临床意义

目的 探讨血清CA25值对子宫内膜癌早期诊断、监测病情变化和预测预后的价值。方法 用免疫化学法检测55例子宫内膜癌患者和16例良性子宫病变患者血清CA125水平。结果 良性子宫病变和44例手术分期为I期的子宫内膜癌患者血清CA125阳性率分别为19．4％和27．3％，两者相比，P＞0．05，无显著性差异（P＞0．05）。手术分期为I期和10例晚期病人（Ⅲ期＋Ⅳ期）血清CA125的阳性率各为27．3％和70％，两者相比，有显著性差异（P＜0．05）。30例Ia期＋Ib期和14例Ic期病人血清CA1254的阳性率分别为20％和47．8％，两者相比，无显著性差异（P＞0．05）。病理分级中30例G1、20例G2、5例G3血清CA1254的阳性率分别为20％、45％、80％，三者相比，相互之间有显著性差异（P＜0．05）。结论 血清CA125的检测对早期诊断子宫内膜癌缺乏敏感性，对早期内膜癌患者预测手术分期，Ic期无明显的参考价值，但与手术分期和病理分级密切相关，可能对预测预后提供一定的参考价值。     

不同部位子宫内膜异位症与血清CA125水平的关系

目的:探讨血清CA125水平与不同部位的子宫内膜异位症之间的相关性。方法:选择经手术或腹腔镜确诊的内异症患者63例和排除内异症的对照组30例,按内异症发生部位的不同分为3组:Ⅰ组(卵巢内异组)34例;Ⅱ组(阴道直肠隔内异组)15例;Ⅲ组(腹壁切口内异组)14例。Ⅳ组为对照组,系临床和病理检查排除了内异症的健康者。术前采取空腹静脉血,用化学发光法测定各组血清中CA125水平。结果:(1)卵巢内异组、阴道直肠内异组的血清CA125水平均显著高于对照组(P<0·05);腹壁切口内异组CA125水平显著低于卵巢内异组(P<0·05),而与阴道直肠隔内异症组、对照组比较无统计学差异(P>0·05);(2)以血清CA125≥35U/ml为临界值,CA125诊断各组内异症的敏感性分别为:卵巢内异症52·94%,阴道直肠内异症40·00%,腹壁切口内异症21·43%。诊断特异性为96·67%。结论:CA125在诊断子宫内膜异位症发生方面具有一定的价值,但并不是敏感指标。单凭血清CA125不能鉴别不同部位的子宫内异症。     

175例子宫内膜异位症患者血清CA125水平的回顾性分析

目的:分析子宫内膜异位症患者合并子宫内膜息肉的情况,探讨血清CA125水平与痛经、内异症rAFS分期、病灶部位的相关性,为临床上更好地解读CA125水平提供依据。方法:回顾性分析2010年1月至12月我院术中或术后病理诊断为子宫内膜异位症的175例患者的临床资料。结果:(1)20.0%的子宫内膜异位症患者合并子宫内膜息肉;(2)36.6%的内异症患者有中、重度痛经,痛经程度与血清CA125水平无相关性;(3)Ⅰ期、Ⅱ期、Ⅲ期、Ⅳ期内异症患者的平均CA125水平分别为21.5U/ml、28.4U/ml、38.6U/ml、57.1U/ml,Ⅲ～Ⅳ期内异症患者血清CA125水平高于Ⅰ～Ⅱ期患者(P<0.05);(4)腹膜型、混合型、卵巢型内异症患者血清CA125的阳性率分别为21.4%、63.0%和67.4%,混合型、卵巢型内异症患者血清CA125阳性率显著高于腹膜型(P<0.001)。结论:血清CA125水平不能作为内异症合并子宫内膜息肉的预测指标;血清CA125水平可用于辅助鉴别内异症的分期和病灶部位,但是CA125对于内异症的早期诊断缺乏敏感性。     

地诺孕素治疗子宫内膜异位症对患者生殖激素及血清CA125水平的影响

目的 探讨地诺孕素治疗子宫内膜异位症对患者生殖激素、血清糖类抗原125(CA125)水平的影响.方法 选取90例子宫内膜异位症患者,按照随机数字表法分成甲组、乙组、丙组,每组30例.患者均实施腹腔镜下保留生育功能手术治疗,术后甲组给予口服地诺孕素6个月,乙组给予注射促性腺激素释放激素类似物(GnRHa)6个月,丙组给予...     

Serum CA 125 levels before, during and after treatment for endometriosis

Objectives: The aim of this study was to assess the treatment of endometriosis with a gonadotropin-releasing hormone (GnRH) agonist in terms of changes to the extent of disease and to CA 125 levels as well as to recurrence during follow-up. Methods: The levels of serum CA 125 were evaluated in 66 patients with endometriosis diagnosed and staged by laparoscopy according to the revised American Fertility Society classification, who received a 6-month course of a GnRH agonist. Serum CA 125 levels were measured before, during (3 and 6 months after the initiation of therapy) and 6 months after cessation of therapy. Results: Patients with minimal and mild endometriosis had significantly higher mean pretreatment values than control subjects in the luteal phase of the cycle or than postmenopausal women (P < 0.05), but the overall mean value was still below 35 U/ml. Levels of CA 125 fell during treatment to those found in normal controls, but rose again after the end of treatment. The sensitivity and specificity of CA 125 were 75% and 83.3%, respectively, and its positive predictive value as a marker of recurrence was 46.36%. Conclusion: These data suggest that CA 125 may be a reliable indicator for monitoring the efficacy of GnRH agonist treatment of endometriosis, but its value as a predictor of recurrence is low, probably due to the suppression of all CA 125 sources such as endometrium, ovaries and implants.     

Tumor tissue CA125 in ovarian carcinoma patients with normal serum levels

A good correlation between elevated serum CA125 and its immunolocalization in ovarian tumor tissue has been reported. This study was undertaken in order to assess the presence of CA125 in tumor tissue obtained from ovarian carcinoma patients with normal serum levels. Eleven such ovarian carcinoma patients (nine of them serous) were identified. In seven the level was normal prior to the initial operation, and in four, prior to a positive second-look operation. Immunohistochemical staining of paraffin sections for CA125 was positive in seven of the tumor tissue samples. Tumor tissue of most ovarian carcinoma patients with a preoperative normal serum CA125 contains the antigen, but an undetermined mechanism prevents elevated serum levels.     

CA 125 normalization with chemotherapy is independently predictive of survival in advanced endometrial cancer

Objective

Changes in CA 125 with chemotherapy predict outcome for epithelial ovarian cancer. There is no such data for advanced endometrial cancer.

Method

Retrospective review of all women receiving carboplatin and paclitaxel for advanced endometrial cancer at any of the institutions of the British Columbia Cancer Agency between September 1995 and September 2006.

Results

185 newly diagnosed women were treated. Univariable analysis for progression-free survival identified as adverse predictors: grade 3, positive residual, age > 60, deep myometrial invasion, increasing stage/substage, papillary serous subtype, presence of cervical involvement, ECOG 1 or greater, CA 125 above 35 either preoperatively or at start of cycle 1 and CA 125 greater than 24 at the start of cycle 3. Upon multivariate analysis, CA 125 above 24 at cycle 3, grade 3 and positive residual remained as independent predictors. The single most important factor identified by decision tree analysis was CA 125 level at cycle 3.

Conclusion

As with epithelial ovarian cancer, changes in CA 125 are highly predictive of outcome for advanced, chemotherapy treated endometrial cancer.